

1 **Title:** Botulinum Toxin Application for Treatment of Graft Vasospasm: A Reverse Translational  
2 Study.

3 **Running title:** The Mechanism of Action, Safety, and Efficacy of BoNT in Human Brain

4 **Authors:** Nadia A. Atai MD/PhD<sup>1</sup>, Kristine Ravina MD<sup>2</sup>, Saman Sizdahkhani MD<sup>3</sup>, Robert

5 Rennert MD<sup>4</sup>, Aidin Abedi MD<sup>5</sup>, Gavin T. Kress MS<sup>6,7</sup>, Federico Fabris PhD<sup>8</sup>, Vincent

6 Nguyen MD<sup>9</sup>, Stan G Louie PhD<sup>10</sup>, Laura Shin MD<sup>11</sup>, Isaac Asante PhD<sup>10</sup>, Debra Hawes MD<sup>12</sup>,

7 Ornella Rossetto PhD<sup>8</sup>, Joseph Carey MD<sup>13</sup>, Jonathan J. Russin MD<sup>1,14\*</sup>

8 **Institutes:**

9 1. Department of Neurological Surgery and Biomedical Engineering, Neurorestoration  
10 Center, Keck School of Medicine, University of Southern California, Los Angeles, CA,  
11 USA

12 2. Department of Neurosurgery, Carilion Clinic, Virginia Tech Carilion School of  
13 Medicine, Roanoke, Virginia, USA

14 3. Department of Neurosurgery, Thomas Jefferson University Hospital, Philadelphia, USA

15 4. Department of Neurosurgery, University of Utah, Salt Lake City, Utah, USA

16 5. Department of Urology, University of Toledo, Toledo, Ohio, USA

17 6. Keck School of Medicine, University of Southern California, Los Angeles, California,  
18 USA

19 7. Icahn School of Medicine at Mount Sinai, New York, NY, USA

20 8. Department of Biomedical Sciences, University of Padova, Italy

21 9. Department of Neurosurgery, University of Rochester Medical Center, Rochester, NY,  
22 USA

23 10. Department of Clinical Pharmacy, Mann School of Pharmacy, University of Southern  
24 California, Los Angeles, California, USA

25 11. Department of General Surgery, Keck School of Medicine, University of Southern  
26 California, Los Angeles, California, USA

27 12. Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles,  
28 California, USA

29 13. Department of Plastic Surgery, Keck School of Medicine, University of Southern  
30 California, Los Angeles, California, USA

31 14. Division of Engineering and Applied Sciences, California Institute of Technology,  
32 Pasadena, CA, USA

33

34 **\*Corresponding Author:**

35 Associate Professor of Neurological Surgery & Biomedical Engineering. Director,  
36 Cerebrovascular Surgery Associate Director, Neurorestoration Center, Keck School of Medicine/  
37 Viterbi School of Engineering University of Southern California. Visiting Associate in Medical  
38 Engineering Division of Engineering and Applied Science California Institute of Technology  
39 1200 N State St # 4250, Los Angeles, CA 90033

40 Phone: (323) 226-2622 /Fax: (323) 442-7543

41 Email: [jonathan.russin@med.usc.edu](mailto:jonathan.russin@med.usc.edu)

42 **Abstract**

43           Vascular graft vasospasm is a lethal risk when using grafts for revascularization and  
44 reconstructive surgery. Revascularization is a treatment modality for ischemic diseases including  
45 Moyamoya disease that requires bypass surgery. Cerebrovascular graft transplantation carries a  
46 5-10% risk of vasospasm, which can lead to devastating neurological sequelae. Here we report  
47 clinical outcomes associated with *ex vivo* botulinum toxin A (BoNT/A) treatment of arterial graft  
48 and provide reverse translational studies investigating the potential mechanisms of action of  
49 BoNT/A to reduce vasospasm. A retrospective review of the maintained database of patients  
50 undergoing surgery was performed for 63 patients. We used paired human vascular graft tissue  
51 for *ex vivo* BoNT/A studies to assess for spasmolytic downstream effectors; cleaved SNAP25,  
52 pMLC, pMYPT, ROCK1/2, and levels of catecholamines. We found that low-dose BoNT/A  
53 graft treatment is associated with 1) a reduction in clinical vasospasm (13.3%,  $p < 0.05$ ) without  
54 any identified safety concerns in patients, 2) an increase in arterial cleaved SNAP25, 3) reduced  
55 levels of pMLC and pMYPT, and 4) reduced levels of catecholamines. The mechanism of action  
56 leading to vascular relaxation is likely through pleiotropic vasodilatory pathways. The  
57 application of BoNT/A as a spasmolytic has potentially safe and broad applications across  
58 multiple surgical and scientific subspecialties.

59

60

61 **Key words: Artery, Botox, Bypass, Brain, Botulinum toxin A, Spasm, Vasospasm,**  
62 **cSNAP25, ROCK.**

63 **Non-standard Abbreviations and Acronyms:** 5HIAA: 5-hydroxyindoleacetic acid; BoNT:  
64 botulinum toxin; DLCFA: descending branch of the lateral circumflex femoral artery; EC-IC:  
65 extracranial-to-intracranial; glmm: generalized linear mixed-level models; IC-IC: intracranial-  
66 to-intracranial; IF: immunofluorescence; IHC: immunohistochemistry; IQR: interquartile range;  
67 LC-MS: liquid chromatography-mass spectrometry; MAP: mean arterial pressure; mRS: modified  
68 Rankin Scale; NT: neurotransmitter; pMLC: phosphorylated myosin light chain; pMYPT1:  
69 phosphorylated myosin phosphatase target subunit 1; RAFCF: radial artery fasciocutaneous  
70 flow-through free flap; RAFF: radial artery fascial flow-through free flap; RAG: radial artery;  
71 rho kinase: ROCK1/2; SAH: subarachnoid hemorrhage; SD: standard deviation; SDS: sodium  
72 dodecyl sulfate; SNAP25: synaptosomal-associated protein 25 kDa; SRM: selected reaction  
73 monitoring; TBS: Tris-buffered saline; TH: tyrosine hydroxylase; VMA: vanillylmandelic acid;  
74 VSMCs: vascular smooth muscle cells.

## 75 **Introduction**

76 Graft vasospasm is a recognized and potentially serious complication after bypass  
77 surgeries.<sup>1</sup> The diagnosis of graft spasm is often made using conventional radiographic imaging  
78 modalities in combination with clinical symptoms.<sup>2</sup> Clinically significant graft spasm was  
79 initially described in coronary bypass surgeries.<sup>3, 4</sup> Revascularization procedures including free  
80 flaps, limb or digital replants, extremity bypass, and cerebral bypass have subsequently reported  
81 vasospasm as a complication<sup>5, 6</sup>

82 Cerebral revascularization is used in the treatment of select complex aneurysms,  
83 medically refractory large vessel stenosis/occlusion, Moyamoya disease, and brain tumor  
84 resections that require vessel sacrifice.<sup>7, 8</sup> Autologous arterial interposition grafts are often used  
85 for medium- to high-flow extracranial-to-intracranial (EC-IC) or intracranial-to-intracranial (IC-  
86 IC) bypass, with arterial grafts generally preferred over venous grafts. This preference is due to  
87 higher long-term patency rates and decreased rates of atherosclerosis and intimal hyperplasia,  
88 best described in the cardiac literature.<sup>9</sup> Arterial grafts are at risk for vasospasm, occurring in up  
89 to 10% of cases, potentially resulting in disabling ischemia for neurosurgical patients<sup>10, 11</sup> To  
90 date, the mechanism of graft spasm remains an area of investigation. Based on animal studies it  
91 is thought to involve multiple pathways. These include temperature fluctuation/mechanical  
92 injury resulting in activation of the ROCK pathway by reactive oxygen species and release of  
93 neuromodulators (Norepinephrine, neuropeptide Y) from sympathetic perivascular nerves by  
94 intracellular calcium concentration.<sup>10, 12, 13</sup> Unlike the transient calcium fluctuation that initiates  
95 vasoconstriction, studies show that the ROCK activation maintains the triggered surge for a  
96 longer period of time, suggesting a spatiotemporal interaction between calcium-mediated  
97 signaling and the ROCK pathway<sup>14</sup> Pathological spasm of arterial grafts can lead to graft

98 occlusion and ischemia. While reported strategies for prevention of vasospasm include the use of  
99 anti-platelet agents, atraumatic harvest techniques, *ex vivo* treatment with short-acting  
100 vasodilators and maintaining an elevated mean arterial pressure (MAP),<sup>15-19</sup> there is no  
101 consensus protocol for spasm prevention.

102 Botulinum toxin (BoNT) is a neurotoxin produced by several species in the bacterial  
103 genus *Clostridium*. It is traditionally classified into seven moieties, four of which (A,B, E, F) can  
104 produce toxic reactions in humans.<sup>20-22</sup> In addition, the A and B varieties are the only type  
105 (BoNT/A, BoNT/B) currently used clinically. Indications include the treatment of chronic  
106 migraine, spastic disorders, cervical dystonia, hyperhidrosis, frown lines, detrusor  
107 hyperactivity<sup>23, 24</sup> and Raynaud's phenomenon.<sup>25-28</sup> Although BoNT primarily works by blocking  
108 acetylcholine release at the neuromuscular junction,<sup>20, 29</sup> pleiotropic effects have been suggested  
109 in pre-clinical studies.<sup>29-32</sup>

110 Our team previously demonstrated *ex vivo* BoNT application for off-label use to prevent  
111 graft spasm in revascularization,<sup>29, 33, 34</sup> theoretically reducing the risk of systemic effects of  
112 BoNT such as anaphylaxis, respiratory insufficiency, and generalized muscle weakness.<sup>35, 36</sup> The  
113 method previously described for prevention of vasospasm with BoNT/A is to incubate the graft  
114 in reconstituted BoNT/A<sup>29, 33</sup>. However, this use is off-label and to our knowledge, no prior  
115 reports have described BoNT/A efficacy and safety related to human cerebral revascularization.  
116 In addition, a knowledge gap exists in understanding the pleiotropic effect of BoNT/A that may  
117 contribute to spasmolysis in human arteries.

118 We herein report the use of BoNT/A in 63 patients undergoing cerebral revascularization  
119 surgery and describe the clinical outcomes compared to historical controls. In addition, we use a  
120 reverse translation approach in human tissue specimens to investigate the mechanism of action of

121 BoNT/A's effect on arterial graft reactivity, focusing on adrenergic signaling and the Rho/ROCK  
122 pathway for smooth muscle contraction.

## 123 **Results**

124 *Characteristics of study participants.* Sixty-three patients (35 women [55%]; mean age  
125  $50.76 \pm 14.06$  years, Table 1) underwent cerebral revascularization surgery, with a total of 66  
126 grafts in 63 patients. BoNT/A was used in 35 patients (37 grafts [56%]). Median follow-up time  
127 was 175 days (interquartile range: 36-936). Indications for bypass included ruptured aneurysm  
128 (35%), ischemia (23%), unruptured aneurysm (21%), moyamoya disease (16%), and tumor (5%)  
129 (Fig. 1 and Table 1). Twenty-five patients presented with strokes, 17 of which were acute. While  
130 most characteristics had no significant differences, notably, the time of the last follow-up  
131 differed significantly at  $p < 0.001$ . In addition, BoNT/A patients were significantly ( $p = 0.007$ )  
132 more likely to have presented with a recurrent stroke, however, there was no significant  
133 difference in the prevalence of recurrent stroke if a stroke was present. BoNT/A patients were  
134 significantly less likely to present with an aneurysm ( $p = 0.004$ ) but more likely to present with  
135 ischemia ( $p = 0.011$ ).

136 *Vasospasm, stroke, mortality, and functional outcomes.* The incidence of clinically  
137 significant graft vasospasm (Fig. S1) was significantly lower in the BoNT/A versus control  
138 groups (0 vs. 13.3%,  $p=0.040$ ). Rates of angiographic spasm were not significantly different  
139 between the BoNT/A and control groups. Inter-observer reliability was low (kappa 0.52 for  
140 dichotomous assessment and 0.36 for the four-point scale), and when the ratings from each  
141 observer were analyzed individually, there was no significant difference between the two groups.  
142 In addition, multinomial logistic regression of discharge disposition versus BoNT/A treatment  
143 revealed that BoNT/A treatment was associated with significantly ( $p = 0.014$ ) lower discharge

144 rate directly home (17.82% vs. 56.61%). The two groups were comparable in terms of 30-day  
145 all-cause stroke rate ( $p=0.951$ ), 30-day all-cause mortality ( $p=0.473$ ), post-operative graft  
146 patency ( $p=1.0$ ), length of hospital stay ( $p=0.756$ ), and improvement in mRS from baseline to  
147 final follow-up ( $p=0.482$ ). A model that considered the different follow-up times for BoNT/A  
148 and control patients did not find a significant difference for mRS.

149 *BoNT/A induced cleavage of SNAP25 in human brain samples.* An antibody specific to  
150 the BoNT/A cleavage product of SNAP25 (Fig. 2A) was used to probe western blotting of  
151 human brain tissues (Fig. 2. B, Fig. S4-S5). This produced a band at the expected kDa as well as  
152 a doublet in the cleaved human product. Immunohistology with the cSNAP25 antibody (Fig. 2C)  
153 revealed a visible increase in cleaved SNAP25 after BoNT/A treatment, as expected.  
154 Densitometry of western blotting (Fig. 2D) showed that BoNT/A treatment resulted in increased  
155 measured cleaved SNAP25 (cSNAP25), which was significant, with a non-significant decrease  
156 in full-length SNAP25. The doublet band in human tissue cleavage product has been reported  
157 and characterized elsewhere, representing cleaved (24kDa) and non-cleaved SNAP25 (25kDa)  
158 depending on the amount of neurotoxin used.<sup>41</sup>

159 *BoNT/A cleavage of human arterial SNAP25.* Upon treatment of arterial graft material  
160 with BoNT/A, we extracted total protein and performed western blotting (Fig. 3A). We did not  
161 quantify these blots because of known wide variations of nerve distribution in arterial tissue  
162 segments and attendant difficulties in normalizing with conventional housekeeping genes such as  
163 GAPDH or  $\beta$ -actin within biologically different individuals. While each sample could be  
164 normalized to its own housekeeping genes, these would not have been comparable to other  
165 biological replicates because of both nerve distribution and heterogeneity of cell activity.  
166 However, in those arterial samples that had uniform morphology (Fig. S6) and SNAP25, we



167 subjected both treated and untreated samples and corresponding controls (Fig. 3B-C) to  
168 immunoassaying for cleaved SNAP25, TH, and DAPI (Fig. 3 B-C). Assessing the percent of  
169 cells with cleaved SNAP25 signal (Fig. 3D), revealed a mean  $14.52\% \pm 5.52\%$  SEM presence of  
170 cells showing cleaved SNAP25 colocalizing with TH. This finding was significant ( $p < 0.001$ ,  $R^2$   
171  $= 0.600$ ).

172 *BoNT/A reduces levels of major neurotransmitters in human arteries.* When we exposed  
173 tissue samples to BoNT/A and measured neurotransmitter levels in arteries with and without  
174 exposure by LC-MS, we found that BoNT/A treatment was associated with a reduction in  
175 multiple (but not all) neurotransmitters in the panel (Fig. 4A-G). Specifically, when analyzed by  
176 paired generalized linear mixed models, with random intercepts for each donor, we found that  
177 BoNT/A administration significantly ( $p \leq 0.05$ ) reduced levels of norepinephrine, epinephrine,  
178 dopamine, glutamine, and 5HIAA. Reduction was between 33% to 65% of untreated levels  
179 (Table 2). Glutamate and VMA level alterations were not significant.

180 *BoNT/A alters ROCK pathway proteins in treated arteries.* We performed western  
181 blotting on Rho kinase (ROCK) and its downstream targets: phosphorylated myosin phosphatase  
182 target subunit 1 (MYPT1), and phospho-myosin light chain 2 (pMLC) in arterial graft samples  
183 collected before and after BoNT/A treatment (Fig. 5A-F, Table 3). We determined that treatment  
184 was associated with a reduction in all three proteins measured but found that the reduction of  
185 ROCK was not significant. We note that the data was generated with two different housekeeping  
186 proteins for normalization to address the possible effects in a supplement.

## 187 **Discussion**

188 Cerebral revascularization using arterial interposition grafts is an important strategy for  
189 the treatment of complex ischemic and non-ischemic vessel pathologies.<sup>1-5</sup> Limb arteries such as  
190 the radial artery are frequently used as interposition grafts due to ease of access and harvest.  
191 These arteries, however, are classified as high-risk "spastic" due to a predominance of  
192 vasoconstrictor receptors, relatively reduced production of vasodilators, and an abundance of  
193 vascular smooth muscle cells (VSMCs).<sup>6,7</sup> Early cerebral revascularization interposition graft  
194 occlusion and spasm occurs in approximately 5-10% of cases despite advancements in surgical  
195 technique and pharmacologic treatment.<sup>4,8,9</sup> Therefore, revascularization graft vasospasm  
196 resulting in recurrent ischemia and/or occlusion remains a potentially lethal complication.<sup>7,10,3,4,8</sup>  
197  
198 Various factors that alter vasomotor tone can provoke arterial narrowing, which can restrict or  
199 prevent blood flow. In physiological conditions, arteries can modify their diameters through  
200 corrective dilation or constriction of the artery to condition the blood supply to vital tissues. This  
201 autoregulation system is challenged in pathologic conditions, such as Prinzmetal's Angina,  
202 Raynaud's Disease, Systemic Sclerosis, Chronic Kidney Disease, Multiple Sclerosis, Buerger's  
203 Disease, preeclampsia, and chemo/radiation-induced vasospasm.<sup>42, 43</sup> Moving beyond disease  
204 context, certain surgeries are intricately linked with a similar mechanism of action of arterial  
205 spasm including but not limited to, cerebral bypass, coronary bypass, carotid bypass, renal  
206 bypass, hepatic bypass, traumatic spinal cord bypass, infrainguinal bypass, and free flap  
207 transplantation in reconstruction surgeries (Table 4).<sup>15, 44-46</sup> Arterial spasm in the context of  
208 bypass surgery is a feared complication that arises from a complex interplay of factors between  
209 the recipient and donor artery in combination with the vessel microenvironment due to the  
210 manipulation and clamping of blood vessels during surgery. This can induce postoperative

211 inflammation and damage to the endothelial lining of blood vessels, and temporary cessation of  
212 blood flow and subsequent reperfusion further heightens the spastic risk.<sup>47</sup> The rate of this  
213 complication in all bypass surgeries is low, but the mortality can be high.<sup>48</sup>

214

215 Primary pharmacologic treatment for vasospasm is currently calcium channel blockers  
216 (CCBs), notably verapamil or diltiazem, serving as frontline agents to induce smooth muscle  
217 relaxation in cerebral and coronary arteries. Sublingual nitroglycerin, a vasodilator, plays a  
218 pivotal role in acute coronary spasm management, with long-acting formulations prescribed for  
219 sustained relief. Isosorbide dinitrate or mononitrate represents an additional avenue for  
220 vasodilation, while beta-blockers, cautiously administered, may be considered to alleviate  
221 arterial workload.<sup>47</sup> Other treatment strategies for vasospasm include intra-arterial drug delivery  
222 and mechanical angioplasty as salvage treatments for graft vasospasm.<sup>8</sup> In cases where these  
223 therapies fall short, a repeat surgical intervention for graft revision can be attempted but this  
224 subjects the patient to accumulating risks and can prolong hospitalization.<sup>8,11</sup> Moreover, the need  
225 for blood pressure maintenance in the postoperative period for cerebrovascular bypass patients  
226 generally limits systemic vasodilator therapy.<sup>5</sup> Additionally, intraoperative preventive and post-  
227 operative salvage vasodilator effects are typically short-lived.<sup>12</sup> Although different variations of  
228 spasmolytic interventions have been proposed for vasospasm in various diseases and surgical  
229 procedures, there currently exists no single effective spasmolytic agent or protocol for graft  
230 vasospasm prevention.<sup>7,10</sup> Recognizing these treatment-induced limitations are pivotal for  
231 anticipating and managing vasospasm in the context of various bypass surgeries while  
232 integrating pharmacologic treatments.

233 In this study, we assessed the effects of *ex vivo* graft treatment with BoNT/A for  
234 preventing graft vasospasm following cerebral revascularization surgery. As previously  
235 described, BoNT primarily works by blocking acetylcholine release at the neuromuscular  
236 junction and is used for multiple medical conditions including headache prophylaxis, urinary  
237 incontinence, hyperhidrosis, hemifacial spasm, spasticity disorders, and dystonia.<sup>20, 29</sup> While  
238 hazards are associated with BoNT/A use, these are primarily due to high dose, frequent use, and  
239 prolonged exposure causing retrograde axonal migration of BoNT from the site of injection.<sup>35, 36</sup>  
240 BoNT/A can prevent arterial spasms in animal pre-clinical studies.<sup>29-32</sup> A recent systematic  
241 review and meta-analysis of controlled animal studies in 1032 animals with various doses of  
242 BoNT/A showed that BoNT/A increases vasodilation in arteries by 40% and in veins by 43%  
243 while decreasing the risk of thrombosis (arteries 85% and veins 76%).<sup>49</sup> The authors concluded  
244 that intraoperative application or pre-treatment with BoNT/A alters the vascular system,  
245 suggesting an expansion of research and clinical use of BoNT/A in human vascular disease and  
246 surgery.

247 Our group reported in 2018 the first 3 human cerebrovascular cases receiving  
248 intraoperative BoNT/A for prevention of cerebrovascular graft vasospasm, demonstrating  
249 feasibility.<sup>34</sup> In the current study we report a significant decrease in the incidence of clinical  
250 vasospasm in the BoNT/A+ group vs controls. No difference was identified in 30-day stroke, all-  
251 cause mortality, or long-term functional recovery as measured by mRS. These findings have  
252 significant implications for the safe performance of revascularization procedures. Our clinical  
253 data analysis did not reveal a significant difference in angiographic vasospasm rates with  
254 BoNT/A graft preparation. This was likely influenced by the poor inter-observer reliability we  
255 encountered, an issue previously described in the assessment of vasospasm following SAH.<sup>50</sup>

256 This decoupling of angiographic and clinical outcomes is also consistent with prior data on the  
257 administration of the calcium channel blocker nimodipine for clinical vasospasm prevention (one  
258 of few therapies shown to improve outcomes after aneurysmal subarachnoid hemorrhage).<sup>51-53</sup>  
259 Although acting via a different mechanism than that posited for BoNT/A (calcium channel  
260 blockade reduces post-synaptic cell contractility), the effect of nimodipine on rates of  
261 radiographic vasospasm is inconsistent, with pleiotropic effects hypothesized outside of direct  
262 effects on large-vessel reactivity.<sup>54-56</sup> Reconciling the notion that BoNT/A primarily acts via pre-  
263 synaptic release of acetylcholine while graft spasm is likely largely adrenergic, i.e.,  
264 norepinephrine release,<sup>29, 33</sup> our results support that BoNT/A acts through pleiotropic  
265 vasodilatory pathways to mitigate clinical vasospasm.

266 Our clinical study was "reverse translated" to evaluate the pleiotropic effects of BoNT/A  
267 on human arterial tissue. A total of 29 human arterial graft samples matched per patient (non-  
268 BoNT/A and BoNT/A arterial segments), were included in this study. We found that BoNT/A  
269 treatment resulted in cleavage of SNAP25 in the graft tissue. Despite quantification being  
270 difficult due to the low concentration of BoNT/A used, low levels of SNAP25 in some arteries,  
271 and heterogenous distribution of nerve terminals, co-localization and quantification of cleaved  
272 SNAP25 was possible in peri-arterial pre-synaptic nerve terminals. Fitting with a decreased pre-  
273 synaptic release of these transmitters from SNAP25 inhibition, BoNT/A treatment was  
274 associated with reduced levels of several neurotransmitters from sympathetic perivascular nerves  
275 in arterial tissue, except glutamate and VMA. The levels of phosphorylated myosin light chain  
276 and phosphorylated myosin phosphatase were also significantly reduced. Although the kinase  
277 ROCK1/2 was overall reduced, this change was not detectable significant.

278           These findings suggest BoNT/A has an impact on several convergent pathways related to  
279 vascular constriction (Fig. 6). The catecholamines, dopamine, norepinephrine, and epinephrine  
280 play important roles in sympathetic nervous activity to induce physiologic vascular constriction,  
281 however, these signaling pathways can become hyperactive under pathologic conditions and  
282 cause cerebral infarctions (i.e., after aneurysmal subarachnoid hemorrhage).<sup>57, 58</sup> Currently,  
283 vascular graft spasm is thought to result in parts from catecholamine release by denervated nerve  
284 endings in the harvested tissue into the perivascular space, which then activates a PLC- $\beta$ /IP<sub>3</sub>/Ca<sup>2+</sup>  
285 contraction pathway via MLC phosphorylation.<sup>59</sup> The demonstrated cleavage of SNAP25 by  
286 BoNT/A resulting decrease in sympathetic perivascular catecholamine levels provides one  
287 mechanistic explanation for the reduction in clinical vasospasm seen in this human trial (Fig. 6).  
288 Modulation of the separate but convergent vasoconstrictive ROCK signaling pathway, activated  
289 by cold and mechanical stimuli, is also suggested by our data. This pathway is likely  
290 contributory to vasospasm as the OR room temperature is maintained at 25°C, as compared to  
291 physiologic body temperature of ~37°. This relative cold can induce ROS, which can activate  
292 ROCK. Additionally, mechanical stimulus, such as graft harvest, can induce activation of the  
293 upstream signaling molecule RhoA, also contributing to ROCK activation.<sup>14</sup> The decrease in  
294 pMYPT1, a key molecule in the ROCK pathway, shown in this work provides an additional  
295 mechanistic explanation for our clinical findings. Finally, the catecholamine and ROCK  
296 pathways merge at the effector molecule MLC and inhibition of MLC phosphorylation has been  
297 shown to prevent vasospasm.<sup>60</sup> The decrease in pMLC seen with BoNT/A application in this  
298 work is consistent with a convergent treatment effect on these pathways. Additional exploration  
299 of alterations in these and other pathways may nonetheless lead to a more refined understanding

300 of the mechanisms of action. Future applications of BoNT/A to reduce post-operative graft  
301 vasospasm and broader applications will likely not be limited to cerebrovascular.

302         There are significant limitations to this study. To our knowledge, this is the first in human  
303 study investigating the transplantation of arterial grafts exposed to BoNT/A intracranially.  
304 Given the novelty of the approach, we were without any prior standardized tissue processing  
305 protocol. In addition, this was a single-center, non-randomized retrospective design with limited  
306 access to human tissue. Human specimens were limited by clinical availability and at times the  
307 tissue volumes were not ideal for mechanistic evaluations and parallel studies with various  
308 methods. Safety concerns also limited our protocol to a single low dose (10 Units/mL) and  
309 operative workflow resulted in short exposure (30 minutes) of BoNT/A.

### 310 **Conclusions**

311         The treatment of human arterial grafts with BoNT/A prior to intracranial transplantation  
312 has a favorable safety profile and reduced rates of clinical vasospasm. A reverse-translational  
313 model demonstrates BoNT/A has a pleiotropic mechanism that cleaves pre-synaptic SNAP-25,  
314 reduces catecholamine levels, and modulates the ROCK pathway.

315

## 316 **Methods**

317 *Retrospective Study Population.* An IRB-approved, prospectively maintained database  
318 was used to identify and consent patients who had undergone EC-IC bypass with an autologous  
319 arterial interposition graft between July 2014 and January 2022. Interposition grafts were treated  
320 with BoNT/A beginning in March 2017. Information obtained included patient demographics,  
321 clinical presentation, indication for bypass, surgery performed, pre- and post-operative imaging  
322 characteristics, clinical outcomes (e.g., modified Rankin Scale [mRS] at follow-up), and  
323 complications.

324 *Surgical Protocol.* All procedures were performed at a single institution by a  
325 multidisciplinary surgical team including neurosurgery and plastic/reconstructive surgery.  
326 Patients were considered candidates for cerebral revascularization after failing conservative  
327 treatment or if lesions were not amenable to traditional microsurgical or endovascular  
328 approaches based on multidisciplinary review. The revascularization strategy (Fig. 1) was  
329 planned through collaboration with the plastic and neurosurgical teams. The donor vessel was  
330 harvested by the plastic surgery team in all cases. Donor vessels included the radial artery  
331 (RAG), radial artery fascial flow-through free flap (RAFF), radial artery fasciocutaneous flow-  
332 through free flap (RAFCF), descending branch of the lateral circumflex femoral artery  
333 (DLCFA), and anterior and posterior tibial arteries. Each graft was treated *ex vivo* with BoNT/A  
334 (Botox, Onabotulinumtoxin A, Allergan Incorporated, Irvine, California), as described herein,  
335 before implantation.<sup>63</sup> All grafts were harvested in a minimal traumatic manner. The adventitia  
336 was removed, and the graft was irrigated and incubated in 100 units of BoNT/A in 10 mL of  
337 sterile normal saline for approximately 30 minutes. Prior to transplantation, it was irrigated with



338 a heparin/milrinone saline solution (10,000 units of heparin with 10 mg of milrinone in 1 liter of  
339 normal saline).

340 *Outcome assessment.* Outcomes assessed included post-operative radiographic and  
341 clinical vasospasm, 30-day all-cause stroke rate, 30-day all-cause mortality, post-operative graft  
342 patency, length of hospital stay, hospital discharge, and changes in modified Rankin Scale (mRS)  
343 from baseline to final follow-up. Radiographic graft vasospasm (Fig. S1) was rated on a  
344 dichotomous (present/absent) and a four-point scale (no vasospasm, mild, moderate, or severe  
345 vasospasm) based on a blinded review of angiographic images by four observers (including two  
346 dual-trained vascular neurosurgeons, one open vascular neurosurgeon, and one neuroradiologist;  
347 excluding the treating surgeon). Clinical graft vasospasm was defined as any new neurologic  
348 deficit that correlated with angiographic spasm of the bypass graft's territory and was not  
349 otherwise explained. This was assessed independently from vasospasm secondary to  
350 subarachnoid hemorrhage (SAH).

351 *Assessing BoNT/A substrate, synaptosomal-associated protein 25 (SNAP-25) cleavage in*  
352 *perivascular adrenergic nerve terminals.* Sequential 4- $\mu$ m-thick surgical sample sections were  
353 prepared from human brain and artery FFPE tissues for immunohistochemistry (IHC, Fig. S2)  
354 and immunofluorescence (IF) staining. Samples were carefully selected based on the matching  
355 size of tissue and intact morphology. Chromogen-based IHC analysis for BoNT/A and full-  
356 length SNAP25 was performed by using an automated staining system (BOND-MAX; Leica  
357 Microsystems, Vista, CA). For IHC analysis, antibodies were titrated on the basis of the  
358 minimum to maximum range of staining negative to positive in the control human brain  
359 specimens. Briefly, slides were fixed with a 16% PFA (EM grade): PBS/dH<sub>2</sub>O at a 1:2:1 ratio for  
360 10 minutes, followed by 3x TBS/dH<sub>2</sub>O resin and soaked in Bond buffer. Slides were loaded in

361 Bond Rx autostainer, ER-1-20m (pH6 retrieval). Rabbit primary Ab for full-length SNAP25 was  
362 applied at 1:200 in artery samples and 1:5000 in brain tissue for 45m. Secondary Ab E41-20m,  
363 Rb DAB for 30m. Slides were unloaded, and coverslips were applied with a solution that  
364 included nuclear staining, DAPI (1:1000), and sealed with nail polish.

365 For detection of BoNT/A-cleaved SNAP-25 in the frozen human brain (positive control,  
366 2 replicates) and vascular tissue (7 replicates), we co-incubated with antibodies against the  
367 adrenergic nerve marker, tyrosine hydroxylase (TH, Fig. S3, S4), using a similar protocol except  
368 that primary antibody was to be a chicken anti-TH (1:200) or a rabbit anti-A-cleaved SNAP25  
369 (1:200). This latter polyclonal antibody has been raised against the C-terminal peptide of SNAP-  
370 25, sequence KADSNKTRIDEANQ (Fig.2A) of SNAP25 which is exposed after BoNT/A  
371 cleavage and is hidden in the intact SNAP25.<sup>36</sup> Immunoexpression of these targets was  
372 quantified and compared in arterial graft subsamples collected before and after BoNT/A  
373 treatment. Images were exported as JPEG files and analyzed using 346 ImageJ software.

374 *Western blotting.* Total protein was isolated from the human cortex and descending  
375 branch of the lateral circumflex femoral artery (DLCFA) tissue samples using the N-PER  
376 Neuronal Protein Extraction Reagent (ThermoFisher 87792) and Cell Lysis Buffer  
377 (ThermoFisher FNN0011) respectively, each supplemented with phenylmethylsulfonyl fluoride  
378 (ThermoFisher 36978) and Pierce Protease and Phosphatase Inhibitors (ThermoFisher A32959)  
379 and homogenized with a Dounce tissue grinder. Proteins were denatured with sodium dodecyl  
380 sulfate (SDS) and heat while disulfide bonds were reduced with 2-Mercaptoethanol before  
381 electrophoretic separation of 20 µg of protein on pre-cast 10%-14% polyacrylamide gels with  
382 Tris-Glycine buffer supplemented with Bolt Antioxidant (ThermoFisher BT0005).

383 Separated proteins were blotted onto activated 0.45  $\mu$ m PVDF membranes in a Bis-Tris  
384 transfer buffer solution with Bolt antioxidant and 10% methanol. Membranes were blocked for 2  
385 hours in Starting Block T20 Tris-buffered Saline (TBS) Blocking Buffer (ThermoFisher 37543)  
386 at 4°C with gentle agitation before overnight incubation with primary antibody diluted in  
387 Blocking Buffer at 4°C with gentle agitation. Five purified polyclonal rabbit antibodies were  
388 incubated at the upper end of the manufacturer-recommended concentration with corresponding  
389 dilutions as follows: rabbit anti-ROCK-1/2 (Millipore Sigma 07-1458) at 1:500 dilution, rabbit  
390 anti-Myosin Light Chain phospho-specific (Ser19) (Millipore Sigma AB3381) at 1:1000  
391 dilution, rabbit anti-phospho-MYPT1 (Thr850) (Millipore Sigma 36-003) at 1:500 dilution,  
392 rabbit anti-GAPDH (Millipore Sigma G9545) at 1:5000 dilution, and rabbit anti-SNAP25  
393 (Millipore Sigma S9684) at 1:5000 dilution. The non-commercial rabbit anti-cleaved-SNAP25  
394 antibody was incubated at 1:500 and 1:1000 dilution. Blots were probed with goat anti-rabbit  
395 IgG (H+L)-HRP conjugate (Bio-Rad 1706515) at 1:3000 dilution for 1 hour after three 10-  
396 minute washes in TBS with 0.05% Tween 20 detergent. After six more 5-minute washes blots  
397 were developed with Pierce Chemiluminescent substrate solution (Thermo Fisher 34580) and  
398 imaged. Images were exported as JPEG files and analyzed using 346 ImageJ software.

399 *Assessing BoNT/A effects on selected neurotransmitter (NT) levels.* Liquid  
400 chromatography-mass spectrometry (LC-MS) was used to determine whether BoNT/A  
401 administration altered NT levels in the arterial graft wall before and after BoNT/A exposure.  
402 Adventitia were removed from the specimens that were used for NT level measurements to  
403 exclude those NT which were released from the nerve terminals. Briefly, the stock solutions of  
404 individual standards were made by weighing approximately 1mg of the original powder for  
405 metanephrine, norepinephrine, epinephrine, and normetanephrine standards (bought from Sigma-

406 Aldrich (St. Louis, MO)) and dissolving in 50% methanol to achieve a concentration level of 1.0  
407 mg/mL. The stock solution was prepared by mixing the individual standards to make a working  
408 solution of 50 ug/mL each. The working solution was used for calibration curves and quality  
409 control standards.

410 The tissue samples were thawed on ice, ~20-60 mg of thawed tissue was sliced off and  
411 placed in a 2 mL screw cap microcentrifuge tube (VWR, Radnor, PA) containing a 5 mm i.d.  
412 clean stainless-steel beads (Qiagen, Hilden, Germany). To every 20-60 mg of tissue, 500  $\mu$ L of  
413 ice-cold MeOH, acetonitrile, and Water (2:2:1) was added. To this suspension, 10  $\mu$ L of  
414 Voriconazole (internal standard at 50 ng/mL) was added. The samples were homogenized on a  
415 TissueLyzer (Qiagen, Hilden, Germany) at 50 Hz for 5 min and centrifuged at 12 000 rpm for 10  
416 min. About 400  $\mu$ L of the supernatant of the tissue extracts were transferred into another  
417 microcentrifuge tube and then evaporated to dryness under a steady stream of filtered and dried  
418 N<sub>2</sub> gas. The dried residues were then reconstituted with 50% methanol (50  $\mu$ L) and centrifuged  
419 to remove any undissolved debris. The analytes were separated and quantified with Agilent 1290  
420 UPLC linked onto a QTRAP Sciex 6500+ LCMS/MS system. For separation, a Kinetex F5  
421 column (2.6  $\mu$ m, 2.1  $\times$ 150 mm, Phenomenex) was used with the following binary mobile phase:  
422 water + 0.01% FA (mobile phase A) and methanol + 0.01% FA (mobile phase B). The gradient  
423 [time (%A/%B)] was programmed as follows: 0 min (99.8/0.2)–2 min (99.8/0.2)–5 min (98/2)–  
424 11 min (75/25)–13 min (2/98)–17 min (2/98)–18 min (0.2/99.8)–20 min (0.2/99.8). An injection  
425 volume of 10  $\mu$ L was used, and the flow rate was held at 0.2 mL/min while the column  
426 temperature was maintained at 30°C. Each of the targeted analytes was identified and quantified  
427 using their unique MRM signatures (m/z 180.1/148.1 for metanephrine; 152.1/107.1 for  
428 norepinephrine; 166.1/107.1 for epinephrine and 166.1/106 for normetanephrine) in positive

429 mode (ESI). The analyses were conducted in electrospray ionization (ESI) positive mode with  
430 curtain gas flow rate set as 35 L/min, Gas 1 flow rate at 60 L/min; Gas 2 gas flow rate at 70  
431 L/min, spray voltage at 2.5 kV, and source temperature at 500 °C.

432

433 *Statistical analysis.* Description and statistical analysis were performed using JMP Pro 15  
434 (SAS Institute Inc., Cary, NC, USA) and R 4.3.1 (R Foundation for Statistical Computing,  
435 Vienna, Austria). For description, continuous variables are described using mean and standard  
436 deviation (SD) or median and interquartile range (IQR), with binary and categorical variables  
437 described using counts and percentages. The kappa method was used for the assessment of inter-  
438 observer reliability. The two groups were compared using generalized linear models for  
439 continuous variables and logistic regression or multinomial logistic regression for binary or  
440 categorical variables, respectively. Analysis of measurements comparing BoNT/A treated and  
441 untreated samples from the same subjects were done with generalized linear mixed-level models  
442 to account for expected intra-subject autocorrelation. Families and links were selected by  
443 comparison by the Akaike Information Criterion (AIC).<sup>37</sup> The R packages *nnet*,<sup>38</sup> *glmmTMB*,<sup>39</sup>  
444 and *MuMIn*<sup>40</sup> were used for multinomial and mixed-level modeling, respectively. Changes in  
445 mRS from baseline to follow-up were compared using a mixed-level generalized linear model,  
446 clustered by patient.

447 **References**

- 448 1. Coronary angioplasty versus medical therapy for angina: the second Randomised  
449 Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants. *Lancet*.  
450 1997;350(9076):461-8. PubMed PMID: 9274581.
- 451 2. Naik MJ, Abu-Omar Y, Alvi A, Wright N, Henderson A, Channon K, Forfar JC, Taggart  
452 DP. Total arterial revascularisation as a primary strategy for coronary artery bypass grafting.  
453 *Postgrad Med J*. 2003;79(927):43-8. doi: 10.1136/pmj.79.927.43. PubMed PMID: 12566552;  
454 PMCID: PMC1742583.
- 455 3. Ginsburg R, Stinson EB, Bristow MR, Schroeder JS. Coronary-artery spasm after  
456 revascularization. *N Engl J Med*. 1981;305(12):699. doi: 10.1056/NEJM198109173051213.  
457 PubMed PMID: 6973694.
- 458 4. Lewis BH, Muller JE, Rutherford J, Mudge GH, Jr., Collins JJ, Jr. Nifedipine for  
459 coronary-artery spasm after revascularization. *N Engl J Med*. 1982;306(16):992-3. doi:  
460 10.1056/NEJM198204223061615. PubMed PMID: 6977722.
- 461 5. Klocker J, Bertoldi A, Benda B, Pellegrini L, Gorny O, Fraedrich G. Outcome after  
462 interposition of vein grafts for arterial repair of extremity injuries in civilians. *J Vasc Surg*.  
463 2014;59(6):1633-7. Epub 20140219. doi: 10.1016/j.jvs.2014.01.006. PubMed PMID: 24560243.
- 464 6. Tukiainen E, Biancari F, Lepantalo M. Lower limb revascularization and free flap  
465 transfer for major ischemic tissue loss. *World J Surg*. 2000;24(12):1531-6. doi:  
466 10.1007/s002680010273. PubMed PMID: 11193719.
- 467 7. Rennert RC, Russin JJ. Rethinking Cerebral Bypass Surgery. *Neurosurg Clin N Am*.  
468 2022;33(4):403-17. Epub 20220911. doi: 10.1016/j.nec.2022.05.004. PubMed PMID: 36229128.

- 469 8. Esposito G, Amin-Hanjani S, Regli L. Role of and Indications for Bypass Surgery After  
470 Carotid Occlusion Surgery Study (COSS)? *Stroke*. 2016;47(1):282-90. Epub 20151210. doi:  
471 10.1161/STROKEAHA.115.008220. PubMed PMID: 26658449.
- 472 9. Carrel T, Winkler B. Current trends in selection of conduits for coronary artery bypass  
473 grafting. *Gen Thorac Cardiovasc Surg*. 2017;65(10):549-56. Epub 20170809. doi:  
474 10.1007/s11748-017-0807-8. PubMed PMID: 28795296.
- 475 10. He GW, Taggart DP. Spasm in Arterial Grafts in Coronary Artery Bypass Grafting  
476 Surgery. *Ann Thorac Surg*. 2016;101(3):1222-9. Epub 20151114. doi:  
477 10.1016/j.athoracsur.2015.09.071. PubMed PMID: 26588865.
- 478 11. Lawton MT, Hamilton MG, Morcos JJ, Spetzler RF. Revascularization and aneurysm  
479 surgery: current techniques, indications, and outcome. *Neurosurgery*. 1996;38(1):83-92;  
480 discussion -4. doi: 10.1097/00006123-199601000-00020. PubMed PMID: 8747955.
- 481 12. Rosenfeldt FL, He GW, Buxton BF, Angus JA. Pharmacology of coronary artery bypass  
482 grafts. *Ann Thorac Surg*. 1999;67(3):878-88. doi: 10.1016/s0003-4975(98)01299-5. PubMed  
483 PMID: 10215263.
- 484 13. Kumari R, Pascalau R, Wang H, Bajpayi S, Yurgel M, Quansah K, Hattar S, Tampakakis  
485 E, Kuruvilla R. Sympathetic NPY controls glucose homeostasis, cold tolerance, and  
486 cardiovascular functions in mice. *bioRxiv*. 2023. Epub 20230726. doi:  
487 10.1101/2023.07.24.550381. PubMed PMID: 37546870; PMCID: PMC10402010.
- 488 14. Imanishi A, Ichise H, Fan C, Nakagawa Y, Kuwahara K, Sumiyama K, Matsuda M, Terai  
489 K. Visualization of Spatially-Controlled Vasospasm by Sympathetic Nerve-Mediated ROCK  
490 Activation. *Am J Pathol*. 2021;191(1):194-203. Epub 20201016. doi:  
491 10.1016/j.ajpath.2020.09.012. PubMed PMID: 33069718.

- 492 15. Tecle NEE, Zammar SG, Hamade YJ, El Ahmadi TY, Aoun RJN, Nanney AD, Batjer  
493 HH, Dumanian GA, Bendok BR. Use of a harvested radial artery graft with preservation of the  
494 vena comitantes to reduce spasm risk and improve graft patency for extracranial to intracranial  
495 bypass: Technical note. *Clin Neurol Neurosurg.* 2016;142:65-71. Epub 20151231. doi:  
496 10.1016/j.clineuro.2015.12.018. PubMed PMID: 26811865.
- 497 16. Houkin K, Kamiyama H, Kuroda S, Ishikawa T, Takahashi A, Abe H. Long-term patency  
498 of radial artery graft bypass for reconstruction of the internal carotid artery. Technical note. *J*  
499 *Neurosurg.* 1999;90(4):786-90. doi: 10.3171/jns.1999.90.4.0786. PubMed PMID: 10193628.
- 500 17. Myers MG, Fremes SE. Prevention of radial artery graft spasm: a survey of Canadian  
501 surgical centres. *Can J Cardiol.* 2003;19(6):677-81. PubMed PMID: 12772018.
- 502 18. Sia SF, Qian Y, Zhang Y, Morgan MK. Mean arterial pressure required for maintaining  
503 patency of extracranial-to-intracranial bypass grafts: an investigation with computational  
504 hemodynamic models-case series. *Neurosurgery.* 2012;71(4):826-31. doi:  
505 10.1227/NEU.0b013e318266e6c2. PubMed PMID: 22791033.
- 506 19. Sundt TM. Principles of preparation of vein bypass grafts to maximize patency. *J*  
507 *Neurosurg.* 1987;66(2):172-80. doi: 10.3171/jns.1987.66.2.0172. PubMed PMID: 3806199.
- 508 20. Rossetto O, Pirazzini M, Montecucco C. Botulinum neurotoxins: genetic, structural and  
509 mechanistic insights. *Nat Rev Microbiol.* 2014;12(8):535-49. Epub 20140630. doi:  
510 10.1038/nrmicro3295. PubMed PMID: 24975322.
- 511 21. Montecucco C, Molgó J. Botulinum neurotoxins: revival of an old killer. *Curr Opin*  
512 *Pharmacol.* 2005;5(3):274-9. doi: 10.1016/j.coph.2004.12.006. PubMed PMID: 15907915.



- 513 22. Lewandowski M, Swierczewska Z, Baranska-Rybak W. Off-Label Use of Botulinum  
514 Toxin in Dermatology-Current State of the Art. *Molecules*. 2022;27(10). Epub 20220513. doi:  
515 10.3390/molecules27103143. PubMed PMID: 35630620; PMCID: PMC9147387.
- 516 23. Lew MF. Review of the FDA-approved uses of botulinum toxins, including data  
517 suggesting efficacy in pain reduction. *Clin J Pain*. 2002;18(6 Suppl):S142-6. doi:  
518 10.1097/00002508-200211001-00005. PubMed PMID: 12569961.
- 519 24. Padda IS, Tadi P. *Botulinum Toxin Florida*: Statpearls Publishing; 2023 [cited 2023].  
520 Available from: <https://www.ncbi.nlm.nih.gov/books/NBK557387/>.
- 521 25. Du W, Zhou M, Zhang C, Sun Q. The efficacy of botulinum toxin A in the treatment of  
522 Raynaud's phenomenon in systemic sclerosis: A randomized self-controlled trial. *Dermatol Ther*.  
523 2022;35(7):e15529. Epub 20220427. doi: 10.1111/dth.15529. PubMed PMID: 35441772.
- 524 26. Ennis D, Ahmad Z, Anderson MA, Johnson SR. Botulinum toxin in the management of  
525 primary and secondary Raynaud's phenomenon. *Best Pract Res Clin Rheumatol*.  
526 2021;35(3):101684. Epub 20210505. doi: 10.1016/j.berh.2021.101684. PubMed PMID:  
527 33965340.
- 528 27. Gallegos JE, Inglesby DC, Young ZT, Herrera FA. Botulinum Toxin for the Treatment of  
529 Intractable Raynaud Phenomenon. *J Hand Surg Am*. 2021;46(1):54-9. Epub 20200916. doi:  
530 10.1016/j.jhsa.2020.07.009. PubMed PMID: 32948347.
- 531 28. Seyedmardani SM, Aghdashi MA, Soltani S, Zonouz GK. Evaluation of Botulinum  
532 Toxin Type A and its Potential Effect on Exacerbated Raynaud's Phenomenon in Hospitalized  
533 Scleroderma Patients. *Curr Rheumatol Rev*. 2022;18(1):48-57. doi:  
534 10.2174/1573397117666211012105611. PubMed PMID: 34636314.

- 535 29. Ravina K, Strickland BA, Rennert RC, Carey JN, Russin JJ. Role of botulinum  
536 neurotoxin-A in cerebral revascularization graft vasospasm prevention: current state of  
537 knowledge. *Neurosurg Focus*. 2019;46(2):E13. doi: 10.3171/2018.11.FOCUS18514. PubMed  
538 PMID: 30717063.
- 539 30. Murakami E, Iwata H, Imaizumi M, Takemura H. Prevention of arterial graft spasm by  
540 botulinum toxin: an in-vitro experiment. *Interact Cardiovasc Thorac Surg*. 2009;9(3):395-8.  
541 Epub 20090629. doi: 10.1510/icvts.2009.207076. PubMed PMID: 19564207.
- 542 31. Yoon J, Yoon ES, Lee BI, Park SH, Kim JW. Anti-vasospastic effects of botulinum toxin  
543 B pretreatment in animal models. *J Plast Surg Hand Surg*. 2019;53(1):25-30. Epub 20181005.  
544 doi: 10.1080/2000656x.2018.1523179. PubMed PMID: 30289017.
- 545 32. Park TH, Park YJ. The Effect of Botulinum Toxin A on Ischemia-Reperfusion Injury in a  
546 Rat Model. *Biomed Res Int*. 2017;2017:1074178. Epub 20170515. doi: 10.1155/2017/1074178.  
547 PubMed PMID: 28589130; PMCID: PMC5447266.
- 548 33. Strickland BA, Rennert RC, Bakhsheshian J, Bulic S, Correa AJ, Amar A, Carey J,  
549 Russin JJ. Botulinum toxin to improve vessel graft patency in cerebral revascularization surgery:  
550 report of 3 cases. *J Neurosurg*. 2018:1-7. Epub 20180201. doi: 10.3171/2017.9.JNS171292.  
551 PubMed PMID: 29498577.
- 552 34. Strickland BA, Rennert RC, Bakhsheshian J, Bulic S, Correa AJ, Amar A, Carey J,  
553 Russin JJ. Botulinum toxin to improve vessel graft patency in cerebral revascularization surgery:  
554 report of 3 cases. *J Neurosurg*. 2019;130(2):566-72. Epub 20180302. doi:  
555 10.3171/2017.9.JNS171292. PubMed PMID: 29498577.
- 556 35. Alimohammadi M, Punga AR. Neurophysiological Measures of Efficacy and Safety for  
557 Botulinum Toxin Injection in Facial and Bulbar Muscles: Special Considerations. *Toxins*

- 558 (Basel). 2017;9(11). Epub 20171030. doi: 10.3390/toxins9110352. PubMed PMID: 29084148;  
559 PMCID: PMC5705967.
- 560 36. Antonucci F, Rossi C, Gianfranceschi L, Rossetto O, Caleo M. Long-distance retrograde  
561 effects of botulinum neurotoxin A. *J Neurosci*. 2008;28(14):3689-96. doi:  
562 10.1523/JNEUROSCI.0375-08.2008. PubMed PMID: 18385327; PMCID: PMC6671090.
- 563 37. Burnham KP, Anderson DR. *Model Selection and Multimodel Inference: A practical*  
564 *information-theoretic approach*. 2 ed. New York: Springer New York; 2002. 488 p.
- 565 38. Beck MW. *NeuralNetTools: Visualization and Analysis Tools for Neural Networks*. *J*  
566 *Stat Softw*. 2018;85(11):1-20. doi: 10.18637/jss.v085.i11. PubMed PMID: 30505247; PMCID:  
567 PMC6262849.
- 568 39. Brooks ME, Kristensen K, van Benthem KJ, Magnusson A, Berg CW, Nielsen A, Skaug  
569 HJ, Mächler M, Bolker BM. glmmTMB balances speed and flexibility among packages for zero-  
570 inflated generalized linear mixed modeling. *The R Journal*. 2017;9(2):378-400.
- 571 40. Bartoń K. MuMIn: Multi-model inference 2024. Available from: [https://CRAN.R-](https://CRAN.R-project.org/package=MuMIn)  
572 [project.org/package=MuMIn](https://CRAN.R-project.org/package=MuMIn).
- 573 41. Morris JL, Jobling P, Gibbins IL. Botulinum neurotoxin A attenuates release of  
574 norepinephrine but not NPY from vasoconstrictor neurons. *Am J Physiol-Heart Circul Physiol*.  
575 2002;283(6):H2627-35. Epub 20020829. doi: 10.1152/ajpheart.00477.2002. PubMed PMID:  
576 12388237.
- 577 42. Van Beek AL, Lim PK, Gear AJL, Pritzker MR. Management of vasospastic disorders  
578 with botulinum toxin A. *Plast Reconstr Surg*. 2007;119(1):217-26. doi:  
579 10.1097/01.prs.0000244860.00674.57. PubMed PMID: 17255677.

- 580 43. Grenda T, Grenda A, Krawczyk P, Kwiatek K. Botulinum toxin in cancer therapy-current  
581 perspectives and limitations. *Appl Microbiol Biotechnol.* 2022;106(2):485-95. Epub 20211224.  
582 doi: 10.1007/s00253-021-11741-w. PubMed PMID: 34951660; PMCID: PMC8763801.
- 583 44. Kocaeli H, Andaluz N, Choutka O, Zuccarello M. Use of radial artery grafts in  
584 extracranial-intracranial revascularization procedures. *Neurosurg Focus.* 2008;24(2):E5. doi:  
585 10.3171/FOC/2008/24/2/E5. PubMed PMID: 18275300.
- 586 45. Sekhar LN, Duff JM, Kalavakonda C, Olding M. Cerebral revascularization using radial  
587 artery grafts for the treatment of complex intracranial aneurysms: techniques and outcomes for  
588 17 patients. *Neurosurgery.* 2001;49(3):646-58; discussion 58-9. doi: 10.1097/00006123-  
589 200109000-00023. PubMed PMID: 11523676.
- 590 46. Surdell DL, Hage ZA, Eddleman CS, Gupta DK, Bendok BR, Batjer HH.  
591 Revascularization for complex intracranial aneurysms. *Neurosurg Focus.* 2008;24(2):E21. doi:  
592 10.3171/FOC.2008.25.2.E21. PubMed PMID: 19072335.
- 593 47. Pasupathy S, Tavella R, Beltrame JF. Myocardial Infarction With Nonobstructive  
594 Coronary Arteries (MINOCA): The Past, Present, and Future Management. *Circulation.*  
595 2017;135(16):1490-3. doi: 10.1161/CIRCULATIONAHA.117.027666. PubMed PMID:  
596 28416521.
- 597 48. Vyas V, Khan A, Singh A. Intractable Left Internal Mammary Artery Spasm After  
598 Coronary Artery Bypass Grafting. *Cureus.* 2020;12(2):e7045. Epub 20200219. doi:  
599 10.7759/cureus.7045. PubMed PMID: 32211276; PMCID: PMC7083257.
- 600 49. Goldberg SH, Gehrman MD, Graham JH. Botulinum Toxin A and B Improve Perfusion,  
601 Increase Flap Survival, Cause Vasodilation, and Prevent Thrombosis: A Systematic Review and

602 Meta-analysis of Controlled Animal Studies. *Hand (N Y)*. 2023;18(1):22-31. Epub 20210227.  
603 doi: 10.1177/1558944721994250. PubMed PMID: 33645294; PMCID: PMC9806538.

604 50. Darsaut TE, Derksen C, Farzin B, Keough MB, Fahed R, Boisseau W, Letourneau-  
605 Guillon L, Januel AC, Weill A, Roy D, Nguyen TN, Finitisis S, Gentric JC, Volders D, Carlson  
606 A, Chow MM, O'Kelly C, Rempel JL, Ashforth RA, Chagnon M, Zehr J, Findlay JM, Gevry G,  
607 Raymond J. Reliability of the Diagnosis of Cerebral Vasospasm Using Catheter Cerebral  
608 Angiography: A Systematic Review and Inter- and Intraobserver Study. *AJNR Am J*  
609 *Neuroradiol*. 2021;42(3):501-7. Epub 20210128. doi: 10.3174/ajnr.A7021. PubMed PMID:  
610 33509923; PMCID: PMC7959441.

611 51. Ehrlich G, Kirschning T, Wenz H, Hegewald AA, Neumaier-Probst E, Seiz-Rosenhagen  
612 M. Outcome of Oral and Intra-arterial Nimodipine Administration After Aneurysmal  
613 Subarachnoid Haemorrhage - A Single-centre Study. *In Vivo*. 2019;33(6):1967-75. doi:  
614 10.21873/invivo.11692. PubMed PMID: 31662526; PMCID: PMC6899118.

615 52. Allen GS, Ahn HS, Preziosi TJ, Battye R, Boone SC, Chou SN, Kelly DL, Weir BK,  
616 Crabbe RA, Lavik PJ, Rosenbloom SB, Dorsey FC, Ingram CR, Mellits DE, Bertsch LA,  
617 Boisvert DP, Hundley MB, Johnson RK, Strom JA, Transou CR. Cerebral arterial spasm--a  
618 controlled trial of nimodipine in patients with subarachnoid hemorrhage. *N Engl J Med*.  
619 1983;308(11):619-24. doi: 10.1056/NEJM198303173081103. PubMed PMID: 6338383.

620 53. Pickard JD, Murray GD, Illingworth R, Shaw MD, Teasdale GM, Foy PM, Humphrey  
621 PR, Lang DA, Nelson R, Richards P. Effect of oral nimodipine on cerebral infarction and  
622 outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. *BMJ*.  
623 1989;298(6674):636-42. doi: 10.1136/bmj.298.6674.636. PubMed PMID: 2496789; PMCID:  
624 PMC1835889.

- 625 54. Philippon J, Grob R, Dageou F, Guggiari M, Rivierez M, Viars P. Prevention of  
626 vasospasm in subarachnoid haemorrhage. A controlled study with nimodipine. *Acta Neurochir*  
627 (Wien). 1986;82(3-4):110-4. doi: 10.1007/BF01456369. PubMed PMID: 3538789.
- 628 55. Petruk KC, West M, Mohr G, Weir BK, Benoit BG, Gentili F, Disney LB, Khan MI,  
629 Grace M, Holness RO. Nimodipine treatment in poor-grade aneurysm patients. Results of a  
630 multicenter double-blind placebo-controlled trial. *J Neurosurg.* 1988;68(4):505-17. doi:  
631 10.3171/jns.1988.68.4.0505. PubMed PMID: 3280746.
- 632 56. Dodd WS, Laurent D, Dumont AS, Hasan DM, Jabbour PM, Starke RM, Hosaka K,  
633 Polifka AJ, Hoh BL, Chalouhi N. Pathophysiology of Delayed Cerebral Ischemia After  
634 Subarachnoid Hemorrhage: A Review. *J Am Heart Assoc.* 2021;10(15):e021845. Epub  
635 20210730. doi: 10.1161/JAHA.121.021845. PubMed PMID: 34325514; PMCID: PMC8475656.
- 636 57. Ogura T, Satoh A, Ooigawa H, Sugiyama T, Takeda R, Fushihara G, Yoshikawa S,  
637 Okada D, Suzuki H, Araki R, Ishihara S, Nishikawa R, Kurita H. Characteristics and prognostic  
638 value of acute catecholamine surge in patients with aneurysmal subarachnoid hemorrhage.  
639 *Neurol Res.* 2012;34(5):484-90. Epub 20120530. doi: 10.1179/1743132812y.0000000033.  
640 PubMed PMID: 22664172.
- 641 58. Cattaneo A, Wipplinger C, Geske C, Semmler F, Wipplinger TM, Griessenauer CJ,  
642 Weiland J, Beez A, Ernestus RI, Westermaier T, Kunze E, Stetter C. Investigating the  
643 relationship between high-dose norepinephrine administration and the incidence of delayed  
644 cerebral infarction in patients with aneurysmal subarachnoid hemorrhage: A single-center  
645 retrospective evaluation. *PLoS One.* 2023;18(3):e0283180. Epub 20230321. doi:  
646 10.1371/journal.pone.0283180. PubMed PMID: 36943859; PMCID: PMC10030022.

- 647 59. Liu Z, Khalil RA. Evolving mechanisms of vascular smooth muscle contraction highlight  
648 key targets in vascular disease. *Biochem Pharmacol.* 2018;153:91-122. Epub 20180213. doi:  
649 10.1016/j.bcp.2018.02.012. PubMed PMID: 29452094; PMCID: PMC5959760.
- 650 60. Hocking KM, Putumbaka G, Wise ES, Cheung-Flynn J, Brophy CM, Komalavilas P.  
651 Papaverine Prevents Vasospasm by Regulation of Myosin Light Chain Phosphorylation and  
652 Actin Polymerization in Human Saphenous Vein. *PLoS One.* 2016;11(5):e0154460. Epub  
653 20160502. doi: 10.1371/journal.pone.0154460. PubMed PMID: 27136356; PMCID:  
654 PMC4852981.
- 655 61. Yuan TY, Chen D, Chen YC, Zhang HF, Niu ZR, Jiao XZ, Xie P, Fang LH, Du GH. A  
656 novel hypertensive crisis rat model established by excessive norepinephrine infusion and the  
657 potential therapeutic effects of Rho-kinase inhibitors on it. *Biomed Pharmacother.*  
658 2019;109:1867-75. Epub 20181126. doi: 10.1016/j.biopha.2018.11.061. PubMed PMID:  
659 30551442.
- 660 62. Qiao YN, He WQ, Chen CP, Zhang CH, Zhao W, Wang P, Zhang L, Wu YZ, Yang X,  
661 Peng YJ, Gao JM, Kamm KE, Stull JT, Zhu MS. Myosin phosphatase target subunit 1 (MYPT1)  
662 regulates the contraction and relaxation of vascular smooth muscle and maintains blood pressure.  
663 *J Biol Chem.* 2014;289(32):22512-23. Epub 20140620. doi: 10.1074/jbc.M113.525444. PubMed  
664 PMID: 24951589; PMCID: PMC4139257.
- 665 63. Zhang L, Lin WJ, Li S, Aoki KR. Complete DNA sequences of the botulinum neurotoxin  
666 complex of *Clostridium botulinum* type A-Hall (Allergan) strain. *Gene.* 2003;315:21-32. doi:  
667 10.1016/s0378-1119(03)00792-3. PubMed PMID: 14557061.
- 668 64. Paravati S, Rosani A, Warrington SJ. *Physiology, Catacholamines*: StatPearls Publishing;  
669 2022 [cited 2023]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK507716/>.

- 670 65. Yoon S, Burkhardt JK, Lawton MT. Long-term patency in cerebral revascularization  
671 surgery: an analysis of a consecutive series of 430 bypasses. *J Neurosurg.* 2018;131(1):80-7. doi:  
672 10.3171/2018.3.Jns172158. PubMed PMID: 30141754.
- 673 66. Collins P, Webb CM, Chong CF, Moat NE. Radial artery versus saphenous vein patency  
674 randomized trial: five-year angiographic follow-up. *Circulation.* 2008;117(22):2859-64. Epub  
675 20080527. doi: 10.1161/circulationaha.107.736215. PubMed PMID: 18506009.
- 676 67. He GW, Taggart DP. Antispastic Management in Arterial Grafts in Coronary Artery  
677 Bypass Grafting Surgery. *Ann Thorac Surg.* 2016;102(2):659-68. Epub 20160617. doi:  
678 10.1016/j.athoracsur.2016.03.017. PubMed PMID: 27319987.
- 679 68. Frontario SC, Hammond BJ, Sagarwala A, Bernik TR. Surgical management for  
680 refractory Raynaud's phenomena, a rare presentation of upper extremity limb ischemia. *Annals*  
681 *of Vascular Surgery - Brief Reports and Innovations.* 2022;2(2):100078. doi:  
682 <https://doi.org/10.1016/j.av surg.2022.100078>.
- 683 69. Kim HP, Han SK, Kim WK. Long-Term Fate of the Anastomosed Digital Artery after  
684 Successful Replantation. *J Korean Soc Plast Reconstr Surg.* 2003;30(2):120-6.
- 685 70. Desai TR, Meyerson SL, Skelly CL, MacKenzie KS, Bassiouny HS, Katz D, McKinsey  
686 JF, Gewertz BL, Schwartz LB. Patency and Limb Salvage After Infrainguinal Bypass With  
687 Severely Compromised ("Blind") Outflow. *Archives of Surgery.* 2001;136(6):635-42. doi:  
688 10.1001/archsurg.136.6.635.
- 689 71. Klocker J, Bertoldi A, Benda B, Pellegrini L, Gorny O, Fraedrich G. Outcome after  
690 interposition of vein grafts for arterial repair of extremity injuries in civilians. *Journal of*  
691 *Vascular Surgery.* 2014;59(6):1633-7. doi: <https://doi.org/10.1016/j.jvs.2014.01.006>.



692 72. Yoon S, Burkhardt JK, Lawton MT. Long-term patency in cerebral revascularization  
693 surgery: an analysis of a consecutive series of 430 bypasses. *J Neurosurg.* 2019;131(1):80-7.  
694 Epub 20180824. doi: 10.3171/2018.3.JNS172158. PubMed PMID: 30141754.

695

696

697 **Acknowledgment:** All original artwork for this manuscript was created by Studio Kayama LLC.

698

699 **Funding:** This publication was made possible by National Institutes of Health R03 grant  
700 #5R03NS113090-02 (JJR) and the Alfred E. Mann Charities, Inc (JJR). Its contents are solely  
701 the responsibility of the authors.

702

703 **Author contributions:**

704 Conceptualization: NAA, KR, SS, RR, JC, JJR

705 Methodology: NAA, KR, RR, AA, GTK, SL, IA, OR, JJR

706 Investigation: NAA, KR, AA, SS, GTK, FF, LS, IA, DH, OR, JC, JJR

707 Visualization: NAA, KR, AA, SS, GTK, FF, VN, DH, OR, JJR

708 Funding acquisition: NAA, KR, RR, JC, JJR

709 Project administration: NAA, KR, SS, LS, OR, JJR

710 Supervision: NAA, SS, RR, SL, LS, DH, OR, JC, JJR

711 Writing – original draft: NAA, KR, SS, RR, AA, JJR

712 Writing – review & editing: NAA, KR, SS, RR, GTK, FF, VN, SL, IA, DH, OR, JC, JJR

713

714 **Competing interests:** None

715

716 **Disclosures:** None

717

718 **Legends to Figures.**

719 **Fig. 1. Illustration of identification of stroke population with various etiology using clinical**

720 **diagnostic characteristics and current workflow for downstream experimental assays.**

721 Clinical image of selected patients with various surgical indications. The superior images show

722 preoperative assessment of the brain pathology and inferior images depict BoNT/A treated graft

723 patency after surgical procedure. The arrow indicates the arterial graft used in the corresponding

724 patient. Star indicates an intracranial permanent clip used for an intracerebral aneurysm.

725 Workflow of the surgical procedure; Upon admission, the patient undergoes a multidisciplinary

726 diagnostic assessment, and surgery is planned based on the pathology. 1) The neurosurgeon

727 identifies the location (surgical site) of the graft transplantation in the brain, 2) the plastic

728 microsurgeon identifies the potential arterial segment to harvest and treats with BoNT/A. After

729 30 minutes in BoNT/A (control saline), the neurosurgeon measures the length required for the

730 surgical transplantation and the remaining unused tissue is collected for downstream analysis in

731 the lab. In the lab, the arterial specimen is aliquoted and processed for various downstream

732 processes to assess the mechanism of action of BoNT/A in arterial graft patency. This assay

733 includes at the protein level; Western Blotting (WB), H&E, immunohistochemistry staining

734 (IHC), immunofluorescence staining (IF), at molecular levels; Liquid chromatography-mass

735 spectrometry (LC-MS) assay.

736 **Fig. 2. Validation of antibody to mouse cleaved SNAP25 for measurement of human**

737 **SNAP25 cleavage by BoNT/A.** A) Alignment of Mouse and Human SNAP-25 protein

738 sequenced, indicating site of BoNT/A cleavage of the target protein. Red letters show specific

739 amino acid differences between human SNAP25a and SNAP25b splicing variants. B) Western

740 blot of BoNT/A treated (+) and untreated (-) human tissue and mouse tissue with low (+) and

741 high dose (+++) BoNT/A. A double band in the BoNT/A treated tissue is indicated. C)  
742 Immunofluorescence of human brain tissue before and after treatment with BoNT/A, probed for  
743 cleaved SNAP25 and DAPI. Note the concentration of cleaved SNAP25 on cell peripheries. D)  
744 Densitometry of GAPDH-adjusted western signal. The graph is for one point per treatment and is  
745 a qualitative presentation of Fig. 2B.

746 **Fig. 3. Western blotting and quantitative immunofluorescence of effects of BoNT/A**  
747 **treatment in human arteries.** A) Qualitative western blotting of human cleaved SNAP25 in  
748 untreated and BoNT/A treated brain cortex and arterial samples. B) Immunofluorescence of  
749 representative human artery without BoNT/A treatment. C) Immunofluorescence of the human  
750 artery with BoNT/A treatment. D) Analysis of cleaved SNAP25 in pre- vs. post-treated arteries  
751 revealed a significant increase in cleaved SNAP25 after treatment (n=5,  $p < 0.05$ ).

752 **Fig. 4. LC-MS of selected neurotransmitters before and after treatment by BoNT/A.**  
753 Arteries were harvested, and adventitia were removed and subsampled for LC-MS. Next, arteries  
754 were treated with BoNT/A (n=4), and treated arteries subjected to LC-MS, all as described  
755 herein. A) Glutamine. B) Glutamate. C) Norepinephrine. D) Epinephrine. E) VMA. F) 5HIAA.  
756 Analysis revealed significant changes in several of the neurotransmitters.


757 **Fig. 5. Western blot of pMLS, pMYT1, and ROCK1/2.** Western blot of arterial samples with  
758 and without BoNT/A treatment, probed with antibodies for A) pMLS, B) pMYT1, and C)  
759 ROCK1/2, as well as GAPDH. Analysis of GAPDH adjusted densitometry for D) pMLS, E)  
760 pMYT1, and F) ROCK1/2 revealed a trend of reduction with BoNT/A treatment, although the  
761 ROCK1/2 trend was not detectable significant (n=6).

762

763 **Fig. 6. Models of spasmolytic pathways induced by BoNT/A to reduce graft**  
764 **vasoconstriction. BoNT/A inhibition of adrenergic and ROCK pathways in vascular**  
765 **smooth muscle cell (VSMC) activity.** Adrenergic VSMC contraction occurs via two pathways  
766 depending on which receptor is activated. Catecholamines binding to the  $\alpha_1$  receptor activates  
767 phospholipase C- $\beta$  (PLC $\beta$ ), which increases intracellular  $\text{Ca}^{2+}$  levels mediating MLCK  
768 activation. NE binding to the  $\alpha_2$  receptor inhibits adenylyl cyclase (AC), subsequently preventing  
769 inactivation of MLCK. This results in phosphorylation of the MLC by MLC kinase (MLCK) to  
770 mediate VSMC contraction. The ROCK pathway is primarily activated by vasoconstrictive  
771 substance binding to a G protein-coupled receptor and activating guanine nucleotide exchange  
772 factor (GEF). It can also be activated by reactive oxygen species (ROS) produced by the VSMC  
773 mitochondria upon cold exposure or via mechanical stimulus. VSMC contraction can also be  
774 promoted by MLCP inactivation by MYPT1, a ROCK downstream effector. Our current study  
775 shows that BoNT/A-mediated (STX A) vasodilation occurs via the inhibition of multiple  
776 synergic pathways. This includes 1 and 2) ROCK pathway inactivation via reduced  
777 phosphorylation of downstream effector MYPT1 (MYPT1p)/MLCP and 3) inhibition of  
778 catecholamines release (Nor/Epi) via cSNAP25, in perivascular space to prevent adrenergic  
779 receptor activation and corresponding downstream pathways in VSMCs.

780


1 **Fig. 1**



2

3

4 **Fig. 2**




5


6

7 **Fig. 3**


**A. Western Blotting of Human Arteries**




**B. Untreated Artery**



**C. Treated Artery**



**D. Difference in SNAP25**




8

9




10 **Fig. 4**



11


12

13 **Fig. 5**



14

15 **Fig. 6**



16

17

1 **Table 1.** Baseline characteristics of study participants

Baseline characteristics	*BoNT/A+		BoNT/A-		p value <sup>†</sup>
	count	%	count	%	
Number of patients	35	55%	28	44%	0.801
Number of grafts	37	56%	29	43%	0.785
Gender (female)	23/35	65%	12/28	42.86	0.069
Stroke at presentation	19	54%	6	21%	0.007
- Acute	14	73%	4	66%	0.540
Pathology/indication					
- Aneurysm	15/36	41%	23/30	76%	<b>0.004</b>
Ruptured	16/36	44%	20/30	66%	0.069
- Ischemia	13/36	36%	3/30	10%	<b>0.011</b>
- Moya Moya	6/36	16%	6/30	20%	0.219
- Tumor	1/36	2%	3/30	10%	0.215
Age at surgery (years)	51.06±14.92		50.39±13.16		0.854
Med. final follow-up (IQR)	9.1 (5.5–52.2)		129.3 (21.2–228.0)		< <b>0.001</b>
Donor artery					
- Common Carotid	1/66	1%			
- External Carotid	9/66	13%			
- Facial	2/66	3%			
- Vertebral	5/66	7%			
- Middle Cerebral	1/66	1%			
- Occipital	1/66	1%			
- Post Inf Cerebellar	1/66	1%			
- Superfic. Temporal	45/66	68%			
- Superior Thyroid	1/66	1%			
Recipient artery					
- Anterior Cerebral	7/66	10%			
- Posterior Cerebral	2/66	3%			
- Middle Cerebral	51/66	77%			
- Post Inf Cerebellar	6/66	9%			
Graft					
- RAG	30/66	45%			
- DLCFA	27/66	40%			
- Post. Tibial Artery	4/66	6%			
- RAFF	3/66	4%			
- RAFCF	1/66	1%			
- Anterior Tibial Artery	1/66	1%			

- 3 \* Abbreviations: BoNT/A+: treated with BoNT/A; BoNT/A-: untreated; Med.: median; IQR:  
4 inter-quartile range; Post Inf: posterior inferior; Superfic.: superficial; RAG: radial artery;  
5 DLCFA: descending branch of the lateral circumflex femoral artery; Post.: posterior; RAFF:  
6 radial artery fascial flow-through free flap; RAFCF: radial artery fasciocutaneous flor-through  
7 free flap.  
8 † Estimated by logistic regression.

9 **Table 2.** Arterial neurotransmitter level changes induced by BoNT/A

Analyte	BoNT/A+*		BoNT/A-		% Change	$g^{\dagger}$	$\chi^2$ (df)	$p^{\ddagger}$
Dopamine	$^{\S}3.955$	$\pm 1.140$	2.572	$\pm 0.742$	-35%	0.625	8.590 (1)	<b>0.005</b>
Glutamine	366.774	$\pm 88.092$	132.462	$\pm 33.395$	-64%	1.528	142.172 (1)	< <b>0.001</b>
Glutamate	957.962	$\pm 543.589$	623.482	$\pm 354.553$	-35%	0.317	2.855 (1)	0.106
Norepinephrine	210.011	$\pm 56.516$	141.592	$\pm 56.516$	-33%	0.526	94.859 (1)	< <b>0.001</b>
Epinephrine	31.078	$\pm 10.601$	10.867	$\pm 3.711$	-65%	1.105	3515.524 (1)	< <b>0.001</b>
VMA	0.466	$\pm 0.261$	0.520	$\pm 0.297$	+12%	-0.085	0.075 (1)	0.785
5HIAA	84.119	$\pm 34.426$	42.022	$\pm 18.835$	-50%	0.659	11.080 (1)	<b>0.002</b>

10  
 11 \*Abbreviations: BoNT/A+: treated with BoNT/A+; BoNT/A-: untreated; VMA:  
 12 vanillylmandelic acid; 5HIAA: 5-hydroxyindoleacetic acid.

13  $^{\dagger}$ Hedge's  $g$  standardized difference.

14  $^{\ddagger}$ Adjusted by Benjamini-Hochberg FDR for 7 simultaneous tests.

15  $^{\S}$ pg/mg tissue, estimated from models.

16  
 17  
 18  
 19  
 20  
 21  
 22

23 **Table 3.** Arterial ROCK pathway protein level changes induced by BoNT/A

Protein	BoNT/A+*		BoNT/A-		% Change	$g^{\dagger}$	$\chi^2$ (df)	$p^{\ddagger}$
pMLC	$^{\S}0.305$	$\pm 0.096$	0.082	$\pm 0.029$	-74%	1.179	55.783 (1)	< <b>0.001</b>
pMYPT1	0.477	$\pm 0.129$	0.228	$\pm 0.106$	-56%	0.792	27.067 (1)	< <b>0.001</b>
ROCK1/2	0.325	$\pm 0.093$	0.284	$\pm 0.100$	-17%	0.160	0.843 (1)	0.358

24  
 25 \*Abbreviations: BoNT/A+: treated with BoNT/A+; BoNT/A-: untreated; pMLC: phosphorylated  
 26 myosin light chain; pMLC: phosphorylated myosin phosphatase; ROCK1/2: rho-associated  
 27 protein kinase.

28  $^{\dagger}$ Hedge's  $g$  standardized difference.

29  $^{\ddagger}$ Adjusted by Benjamini-Hochberg FDR for 3 simultaneous tests.

30  $^{\S}$ Densitometry, estimated from models.

31

32 **Table 4.** Surgical Vasospasm indications that may benefit from BoNT/A graft pre-treatment

<b>Indication</b>	<b>Type(s) of Vessel</b>	<b>Primary Patency Rate</b>	<b>Common Causes of Reduction of Patency</b>
Cerebral Revascularization <sup>65</sup> ,	Radial Artery	94%	Stroke/Vasospasm
	Saphenous Vein	93%	Stroke
Coronary Artery Bypass <sup>66, 67</sup>	Radial Artery	98%	Thrombosis, Vasospasm
	Saphenous Vein	86%	Thrombosis
Raynaud's Syndrome <sup>68</sup>	Varies	83%	Thrombosis
Free Flap <sup>6</sup>	Varies	82%	Infection, Thrombosis, Technical Error
Digital Replant <sup>69</sup>	Varies	63%	Technical challenges associated with the site/mechanism of injury
Infrainguinal Bypass <sup>70</sup>	Femoral artery	63%	Neointimal Hyperplasia, Thrombosis, Technical Error
Revascularization for Traumatic Injury <sup>71,72</sup>	Varies	93%	Technical error, Thrombosis

33